References
- Bahar FG, Ohura K, Ogihara T, Imai T. (2012). Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci 101:3979–88
- Carlson LA. (2005). Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258:94–114
- Dib JG, Dedeyan S. (2004). Purported benefits of inositol niacinate. Am J Health-Syst Pharm 61:307–8
- Harthon JL, Brattsand R. (1979). Enzymatic hydrolysis of pentaerythritoltetranicotinate and meso-inositolhexanicotinate in blood and tissues. Arzneimittelforschung 29:1859–62
- Harthon JL, Lindqvist JT. (1964). Uber die ausscheidung unresorbietern hexanicotinaureesters von m-inosit in den Feaces. Arzneimittelforschung 14:1170–1
- Head KA. (1996). Inositol hexaniacinate: a safer alternative to niacin. Alternative Med Rev 1:176–84
- Jacobson TA. (2010). A “hot” topic in dyslipidemia management – “how to beat a flush”: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Mayo Clin 85:365–79
- Liang D, Ma J, Wei B, et al. (2008). Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. J Chromatogr B 863:172–6
- Mckenney JM. (2003). Niacin for dyslipidemia: considerations in product selection. Am J Health-Syst Pharm 60:995–1005
- McKenney JM. (2004). New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164:697–705
- Meyers CD, Carr MC, Part S, Brunzell JD. (2003). Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 139:996–1002
- Pieper JA. (2003). Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health-Syst Pharm 60:S9–14
- Piepho RW. (2000). The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 86:35L–40L
- Rittiod T, Hatanaka T, Kagami N, et al. (1999). Simultaneous transport and metabolism of nicotinic acid derivayives in hairless mouse skin. Biol Pharm Bull 22:305–9
- Salvi A, Carrupt P, Mayer JM, Testa B. (1997). Esterase-like activity of human albumin toward prodrug esters of nicotinic acid. Drug Metab Disp 25:395–8
- EFSA. (2009). Scientific opinion of the panel on food additives and nutrient sources added to food on inositol hexanicotinate (inositol hexaniacinate) as a source of niacin (vitamin B3) added for nutritional purpose in food supplements following a request from the European Commission. EFSA J 949:1–20